5622 results about "Receptor" patented technology

The invention discloses a ligand information generation model training method and device and a ligand information generation method and device, and belongs to the technical field of artificial intelligence. The method comprises the following steps: acquiring sample receptor information and sample ligand information, wherein the binding affinity between a ligand described by the sample ligand information and a receptor described by the sample receptor information is not less than a set affinity; denoising the reference noise data based on the sample receptor information through a to-be-trained neural network model to obtain predicted ligand information; determining a first loss for characterizing a difference between the sample ligand information and the predicted ligand information; and training the neural network model based on the first loss to obtain a ligand information generation model. The reference ligand information can be generated based on the reference receptor information through the ligand information generation model, and the binding affinity between the ligand described by the reference ligand information and the receptor described by the reference receptor information is high.

The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and / or degradation and uses of the same in the treatment various diseases.

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.

The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more engineered receptors to immune effector cells in vivo.

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

The invention relates to the field of enzyme engineering, in particular to modified xylanase, a DNA (deoxyribonucleic acid) molecule, a recombinant plasmid and a transfected cell. The modified xylanase protected by the application is formed by replacing a deletion segment of a receptor enzyme with a substitution segment, the receptor enzyme is wild type xylanase, the sequence of the receptor enzyme is SEQ ID NO: 1, the deletion segment comprises a carbohydrate binding module of the receptor enzyme, the substitution segment is a carbohydrate binding module of a donor enzyme, the donor enzyme is a carbohydrate active enzyme, and the donor enzyme is a carbohydrate active enzyme. The sequence of the donor enzyme is one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5. The carbohydrate binding module of the carbohydrate active enzyme with relatively high activity is replaced into the receptor enzyme, so that the binding capacity of the receptor enzyme and the carbohydrate is improved, and the activity of the receptor enzyme is improved.

The invention discloses a fatty acid modified coronavirus antigen and application thereof, and belongs to the field of biological medicine. The fatty acid modified coronavirus antigen contains fatty acid modified N-terminal cysteine (Cys) and a coronavirus antigen, and can contain a connecting structural domain; the coronavirus antigen is a coronavirus spike protein (S protein) receptor binding domain (RBD). The fatty acid modified coronavirus S protein RBD can be self-polymerized into nanoparticles, and compared with the RBD which is not subjected to fatty acid modification, the antigen can induce faster and higher humoral immunity through injection immunity, can induce mucosal immunity and humoral immunity through respiratory tract atomization immunity, and is a candidate mucosal vaccine with potential medical value.

The invention discloses a cherax quadricarinatus oocyte targeted penetrating peptide VgSP and a living body delivery method thereof, and belongs to the technical field of biology. The invention provides the cherax quadricarinatus oocyte targeted penetrating peptide VgSP on one hand, and provides application of the cherax quadricarinatus oocyte targeted penetrating peptide VgSP on the other hand. The invention provides a polypeptide VgSP capable of being recognized by a cherax quadricarinatus oocyte surface receptor and mediated into an oocyte, and an injection and detection method of the polypeptide in sub-adult and adult female cherax quadricarinatus. The breakthrough lays a technical foundation for establishing a gene editing element delivery method with oocyte targeting, and is expected to be applied to the field of cherax quadricarinatus gene editing.

The invention belongs to the technical field of polypeptides, and discloses a polypeptide targeting HER2 protein, a radioactive polypeptide and a preparation method and application of the radioactive polypeptide, and the structural formula of the radioactive polypeptide is as follows: # imgabs0 #. Through in-vitro radiochemical property research and in-vivo stability research, the 68Ga-DOTA-AON is found to be high in stability and hydrophilic; through cell uptake research and receptor binding force research, the 68Ga-DOTA-AON is found to have relatively high affinity to HER2 protein expressed by HT-29 cells; the tumor imaging effect of the radioactive polypeptide 68Ga-DOTA-AON is investigated through small animal PET / CT, and it is found that [68Ga] Ga-DOTA-AON can be used for in-vivo imaging of HER2 positive colorectal cancer.

The invention belongs to the field of mushroom active peptides. The invention provides a Stropharia rugoso-annulata umami peptide as well as a screening method and application thereof. The amino acid sequence of the Stropharia rugoso-annulata umami peptide is KAELDLH and / or LGKSEDDVSK. The freshness threshold value of the stropharia rugoso-annulata freshness peptide ranges from 0.15 mM to 0.23 mM, and the stropharia rugoso-annulata freshness peptide has high freshness activity, is small in molecular weight, capable of being more easily perceived by human body sensory taste bud receptors, safe and non-toxic, can serve as a preparation raw material of seasonings and plant meat and has the freshness increasing effect when cooperating with MSG. The invention provides an effective and practical method for further deep excavation of the Stropharia rugoso-annulata umami peptide, provides a new umami peptide raw material for development of seasonings, and has important application value.

The invention provides a culture medium for immune cells as well as a preparation method and application thereof. On the basis of a serum-free culture medium, a specific additive is added into the culture medium and is used as a nutrient substance for growth of immune cells, so that the concentrations of various components in the final culture medium are fixed, the culture efficiency of the immune cells is improved, the cell activity is increased, and the repeatability of subsequent experiments is ensured. Meanwhile, due to the use of a specific additive, animal serum protein added into a conventional culture medium is avoided, so that the risk of infection of exogenous viruses and pathogenic factors is avoided, the immune cells obtained by culture have no sensitization, and the condition that a receptor is allergic to exogenous serum is avoided. In addition, the cost of the immune cell culture medium is reduced, and the preparation process of the culture medium is simplified. Compared with the prior art, the additive provided by the invention can be preserved for a long time in a low-temperature environment, the activity is kept unchanged, and the additive can be taken and used when a culture medium is prepared, so that the preservation cost of immune cells is effectively reduced.

The invention relates to antarctic krill peptide with umami and an antarctic krill peptide mixture as well as a preparation method and application thereof. Specifically, the amino acid sequence of the euphausia superba peptide is shown as any one of SEQ ID NO: 1-5. The euphausia superba peptide mixture with delicate flavor is obtained by carrying out enzyme digestion treatment on an euphausia superba peptide solution by using incision enzyme, excision enzyme and freshness enhancing enzyme and harvesting supernate. Molecular docking simulation shows that the euphausia superba peptide disclosed by the invention can be combined with a delicate flavor receptor T1R1 / T1R3. The Antarctic krill peptide and the Antarctic krill peptide mixture can be used for development of umami seasonings, and a new idea is provided for development of marine seasonings.

The invention discloses sea cucumber gonad-derived antioxidant peptide as well as a preparation method and application thereof, and belongs to the technical field of food biology. The antioxidant peptide is obtained by carrying out enzymolysis and molecular docking screening on sea cucumber gonads, and comprises at least one of peptides with amino acid sequences as shown in SEQ.ID.NO.1-4. Wherein the docking energy of the SEQ.ID.NO.1 and the receptor SOD is-7.5 kcal / mol, the docking energy of the SEQ.ID.NO.2 and the receptor SOD is-7.5 kcal / mol, the docking energy of the SEQ.ID.NO.3 and the receptor SOD is-7.4 kcal / mol, and the docking energy of the SEQ.ID.NO.4 and the receptor SOD is-7.2 kcal / mol. Tests prove that the antioxidant peptide has high antioxidant activity and has wide application space in the field of functional food.

The present disclosure provides in some embodiments, a multi -objective binder design framework by aligning autoregressive molecular foundation models (e.g., protein language models (pLMs)) to different objectives, such as binding and developability considerations. In some embodiments, direct preference optimization (DPO) can be utilized in the methods and systems described herein to encode multiple design objectives in the language model through direct optimization on expert curated preference sequence datasets comprising preferred and dispreferred distributions. In some embodiments, utilizing the described framework can enable molecular foundation models (e.g., protein language models), such as ProtGPT2, to effectively design binders conditioned on specified receptors and one or more drug developability criteria. Besides being multi -objective, in some embodiments, the methods and systems provided herein conceive online lab-in-the-loop design pipelines by actively incorporating experimental feedback.

The invention discloses a method for restoring soil heavy metal pollution by coupling soybean urease with a charcoal cementing agent, and relates to the technical field of soil heavy metal pollution restoration, and the method comprises the following steps: dynamic microbiome regulation and control: introducing photosensitive protein into soil functional bacteria; the acyl homoserine lactone analogue is synthesized and applied to soil, and is competitively combined with a microbial quorum sensing receptor to block an inhibitor to secrete a signal channel; according to the method, microbial urease secretion is regulated and controlled through optogenetics, an inhibitor signal is blocked through quorum sensing interference, and a microbiome is precisely regulated and controlled; the pH-responsive nanocapsule releases an inhibitor in a targeted manner, and the magnetic-responsive nanochain dynamically captures interfering bacteria, so that the limitation of passive adsorption is broken through; the gene editing plant releases coumarin to inhibit fungal metabolism, and the engineering mycorrhizal fungi physically shields an inhibitor to construct cross-biosphere cooperative defense; the urease activity and the heavy metal removal rate are remarkably improved, meanwhile, the soil microbial diversity is maintained, and the soil specificity interference problem is solved.

The invention belongs to the technical field of immunology, and particularly relates to an anti-IL-6 humanized nano antibody, a recombinant humanized nano antibody and application. The inventor-derived nano antibody 2H3 comprises complementary determining regions CDR1-CDR3, the amino acid sequence of the CDR1 is as shown in SEQ ID NO.13, the amino acid sequence of the CDR2 is as shown in SEQ ID NO.14, and the amino acid sequence of the CDR3 is as shown in SEQ ID NO.15. The inventor-derived nano antibody 2H3 has the advantages that the complementary determining regions CDR1-CDR3 can be used for preparing the antibody; the humanized nano antibody can block the combination of IL-6 and a receptor thereof while keeping the affinity with IL-6, and has a wide application prospect in the preparation of medicines for preventing and / or treating tumors. The humanized nano antibody is low in molecular weight, reduces the immune risk caused by heterology, is more beneficial to penetrating a blood brain barrier, and is easier to reach the interior of a tumor to play a therapeutic effect.

The invention discloses a tumor cholesterol metabolism regulation microneedle patch and a preparation method, the microneedle patch comprises a needle tip and a backing which are connected, the needle tip comprises a needle tip body and nanoparticles loaded on the needle tip body, the nanoparticle is a manganese ion-doped organic metal framework, the outer layer of the manganese ion-doped organic metal framework is modified with a targeting agent, cholesterol oxidase and superoxide dismutase are carried on the manganese ion-doped organic metal framework, the targeting agent can target a CD44 receptor, and the organic metal framework can carry drugs. The targeted drug can enter tumor cells in a targeted mode, superoxide dismutase catalyzes superoxide anions overexpressed in the tumor cells to generate H2O2 and O2, O2 needed by catalysis is provided for cholesterol oxidase, cholesterol at the tumor site is consumed by the cholesterol oxidase, accumulation of 7-DHC is reduced, meanwhile H2O2 can be generated, and the cholesterol oxidase can be used for catalyzing the tumor site. H2O2 is catalyzed by manganese ions through a Fenton-like reaction to generate OH to induce tumor cells to generate ferroptosis, so that ferroptosis-immune synergistic treatment is realized.

The invention provides BiTE for tumor targeted immunotherapy and a preparation method and application, and relates to the technical field of biological pharmacy, the BiTE is obtained by coupling a nano antibody and fusion protein, the C terminal of the nano antibody contains an amino acid sequence SEQ ID No.3, and the BiTE has the function of targeting a human epidermal growth factor receptor on tumor cells; the fusion protein also targets a CD3 receptor on a T cell, activates the T cell, connects the T cell with a tumor cell in time and space, activates the T cell, secretes perforin and granzyme B to kill the tumor cell, and plays a role in targeted immunotherapy. The isopeptide bond is used for coupling the nano antibody and the fusion protein, coupling can be completed within 15 min, the coupling efficiency is 100%, and the in-vivo half-life period of the nano antibody can be prolonged by 6 times.

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).

The invention discloses a method and device for predicting protein-ligand binding affinity based on distance and atomic contact number, comprising: acquiring a data set of protein-ligand binding affinity, the data set comprising: atomic information of a protein receptor and atomic information of a ligand; classifying atoms of a protein-ligand compound in the data set according to a preset atom type, and calculating a distance and an atom contact number of an atom pair of a protein-ligand in the data set according to the atom type; training a preset model by taking the protein-ligand distance and the atom contact number as training data to obtain a protein-ligand binding affinity prediction model; and obtaining to-be-predicted protein-ligand data information, inputting the to-be-predicted protein-ligand data information into the protein-ligand binding affinity prediction model, and outputting the to-be-predicted protein-ligand binding affinity. The method is not limited to the power exponent of the distance in the traditional electrostatic interaction energy and Van der Waals interaction energy, and the prediction capability of the affinity is improved.

The invention provides a micromolecular multifunctional information peptide and application thereof, and belongs to the technical field of active peptide raw material development. The sequence of the small-molecule multifunctional information peptide is VHPYVPR, the small-molecule multifunctional information peptide can be effectively combined with a downstream receptor of EGF, the EGF function is simulated, and meanwhile the situation that use of existing cell growth factor raw materials in the field of cosmetics is limited due to the molecular weight problem is avoided. Experiments prove that the micromolecular multifunctional information peptide provided by the invention can promote the repair of skin damage phenomena such as scratches, inhibit the release of inflammatory factors, inhibit the activity of beta-galactosidase and promote the generation of I-type, III-type and XVII-type collagen, shows excellent repair, soothing and anti-aging functions, is high in permeability and has a wide application prospect.

Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and / or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.

The invention provides a system for evaluating an ADE effect in vitro and application of the system. The system comprises: (i) and (iii); (ii) and (iii); or (i), (ii) and (iii); in one embodiment, the present invention relates to a cell comprising: (i) an SARS-CoV-2 pseudovirus, (ii) an antibody that targets the receptor binding domain of SARS-CoV-2, and (iii) a cell that overexpresses CD32B; the cells are CHO cells. The system provided by the invention can be used for evaluating the ADE effect of the to-be-detected SARS-CoV-2 or the pseudovirus prepared from the to-be-detected SARS-CoV-2 or the antibody targeting the SARS-CoV-2, and has the advantage of higher sensitivity compared with a system based on cells expressing CD32A. The ADE evaluation system has a wide detection range, and can evaluate the ADE effect caused by the action of the SARS-CoV-2 virus or the pseudovirus prepared from the SARS-CoV-2 virus on CHO-CD32B in the presence of the RBD antibody with a wide concentration range (16 ng / mL-10000 ng / mL).

The invention relates to the technical field of organic photoelectric materials, in particular to an acceptor material containing a cyclohexyl side chain, the structural formula of the acceptor material containing the cyclohexyl side chain is one of Y-C1 or Y-C2, and the acceptor material containing the cyclohexyl side chain is # imgabs0. On the basis of a traditional A-D-A structure with a Y series analogue as a core, a large-volume steric hindrance side chain is introduced, and a large-volume cyclohexyl group is introduced into the side chain, so that the acceptor material containing the cyclohexyl side chain is obtained. The organic small molecule acceptor material has the advantages that the steric effect is increased, the intramolecular and intermolecular interaction is adjusted, the polarizability of molecules is enhanced, the intermolecular electron orbital overlapping is promoted, the delocalization of charge transfer pathways is promoted, the energy loss is further reduced, and the efficiency is improved; the material has excellent charge transfer characteristic and good intermolecular accumulation effect, is beneficial to the improvement of charge mobility, and has better photovoltaic performance in the test of a ternary organic solar cell.

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The invention belongs to the technical field of targeting exosome preparation, and particularly relates to a targeting modification method of a rose exosome, a hyaluronic acid modified rose exosome and application of the hyaluronic acid modified rose exosome. The method comprises the following steps: dissolving hyaluronic acid in a rose exosome, adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and N-hydroxysuccinimide, carrying out a reaction for 8-16 h, carrying out centrifugation, and carrying out resuspension precipitation so as to obtain a hyaluronic acid modified rose exosome; the volume mass ratio of the hyaluronic acid to the rose exosome solution is 1 mg: (0.5-1) ml, and the hyaluronic acid, the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and the N-hydroxysuccinimide are in an equal molar ratio. The characteristic that hyaluronic acid is highly compatible with an inflammatory cell CD44 receptor is utilized, the targeting property of the rose exosome to inflammatory cells is enhanced, and the utilization rate and the anti-inflammatory effect of the rose exosome are further improved.

The present disclosure relates HER2 antibodies and to the de novo design of structure-based design targeted antibodies. According to the current disclosure, computer-implemented methods of designing an antibody sequences that will bind the HER2 with significant affinity at a target receptor epitope are disclosed. The method utilizes artificial intelligence (Al) and machine learning (ML) models that are trained to predict improved biomolecule (e.g., antibody or antibody fragments) binding sequences or other desirable properties using known biomolecule / binding partner complexes. A designed HER2 antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.

The present disclosure relates to compounds that elicit degradation of proteins directed against the protooncogene tyrosine protein kinase receptor (RET), which may be a wild-type RET or a mutant form of RET, including compounds of formula (I), for use in the treatment of diseases and conditions mediated by said proteins. # imgabs0 #

The invention discloses a salty taste enhancing peptide. The amino acid sequence of the salty taste enhancing peptide is YD, VR, DA, RVR or any one of SEQ ID NO: 1 to SEQ ID NO: 12. The salty taste enhancing peptide is derived from the part with the molecular weight smaller than or equal to 3000Da in substances obtained after enzymolysis of soft-shelled turtle eggs, has excellent binding energy with salty taste receptors ENaC receptor, TRPV1 receptor and TMC4 receptor and can be tightly combined with the salty taste receptors, a salty taste enhancing peptide solution with the concentration of 0.1% (g / mL) has a remarkable salty taste enhancing effect on a NaCl solution, salty taste sense can be effectively adjusted, and the salty taste enhancing peptide can be used for improving the salty taste of the soft-shelled turtle eggs. Therefore, the salt intake is reduced, the salty taste is not reduced, and the purposes of reducing salt and not reducing salty taste are achieved.